APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Safety and Pharmacovigilance (PV) Software

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug Safety and Pharmacovigilance (PV) Software Market Analysis and Forecast 2026-2032

15 April 2026250 pages

Choose your research edition.

Industry ResearchDrug Safety and Pharmacovigilance (PV) Software Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Safety and Pharmacovigilance (PV) Software Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Drug Safety and Pharmacovigilance (PV) Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Safety and Pharmacovigilance (PV) Software Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Drug Safety and Pharmacovigilance (PV) Software Market Analysis and Forecast 2026-2032250 pages · $4,950 USD

Market perspective

The global Drug Safety and Pharmacovigilance (PV) Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug Safety and Pharmacovigilance (PV) Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug Safety and Pharmacovigilance (PV) Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug Safety and Pharmacovigilance (PV) Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug Safety and Pharmacovigilance (PV) Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug Safety and Pharmacovigilance (PV) Software include Oracle, Veeva Systems, ArisGlobal, IQVIA, EXTEDO, RxLogix, Ennov, Uppsala Monitoring Centre and Medidata, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug Safety and Pharmacovigilance (PV) Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug Safety and Pharmacovigilance (PV) Software, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Safety and Pharmacovigilance (PV) Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug Safety and Pharmacovigilance (PV) Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Safety and Pharmacovigilance (PV) Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Safety and Pharmacovigilance (PV) Software revenue, projected growth trends, production technology, application and end-user industry.

Drug Safety and Pharmacovigilance (PV) Software Segment by Company

Oracle

Veeva Systems

ArisGlobal

IQVIA

EXTEDO

RxLogix

Ennov

Uppsala Monitoring Centre

Medidata

Clarivate

AB Cube

Cloudbyz

Cognizant Technology

Taimei Technology

eMedyun

Bioknow

Singedi Health

Drug Safety and Pharmacovigilance (PV) Software Segment by Type

On-Premises

Cloud-Based

Drug Safety and Pharmacovigilance (PV) Software Segment by Application

Pharma and Biotech Companies

Contract Research Organizations (CROs)

Business Process Outsourcing (BPO) Firms

Other

Drug Safety and Pharmacovigilance (PV) Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Safety and Pharmacovigilance (PV) Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Safety and Pharmacovigilance (PV) Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Safety and Pharmacovigilance (PV) Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug Safety and Pharmacovigilance (PV) Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug Safety and Pharmacovigilance (PV) Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Safety and Pharmacovigilance (PV) Software revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. On-Premises Major Player Table 3. Cloud-Based Major Player Table 4. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharma and Biotech Companies Major Player Table 6. Contract Research Organizations (CROs) Major Player Table 7. Business Process Outsourcing (BPO) Firms Major Player Table 8. Other Major Player Table 9. Drug Safety and Pharmacovigilance (PV) Software Industry Trends Table 10. Drug Safety and Pharmacovigilance (PV) Software Industry Drivers Table 11. Drug Safety and Pharmacovigilance (PV) Software Industry Opportunities and Challenges Table 12. Drug Safety and Pharmacovigilance (PV) Software Industry Restraints Table 13. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drug Safety and Pharmacovigilance (PV) Software Market Share by Region (2021-2026) Table 16. Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drug Safety and Pharmacovigilance (PV) Software Market Share by Region (2027-2032) Table 18. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Players (2021-2026) Table 20. Global Drug Safety and Pharmacovigilance (PV) Software Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drug Safety and Pharmacovigilance (PV) Software Key Players Headquarters & Area Served Table 22. Global Drug Safety and Pharmacovigilance (PV) Software Players, Product Type & Application Table 23. Global Drug Safety and Pharmacovigilance (PV) Software Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drug Safety and Pharmacovigilance (PV) Software by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Type (2021-2026) Table 30. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Type (2027-2032) Table 31. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Application (2021-2026) Table 35. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Application (2027-2032) Table 36. Oracle Company Information Table 37. Oracle Business Overview Table 38. Oracle Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Oracle Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 40. Oracle Recent Development Table 41. Veeva Systems Company Information Table 42. Veeva Systems Business Overview Table 43. Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 45. Veeva Systems Recent Development Table 46. ArisGlobal Company Information Table 47. ArisGlobal Business Overview Table 48. ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 50. ArisGlobal Recent Development Table 51. IQVIA Company Information Table 52. IQVIA Business Overview Table 53. IQVIA Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. IQVIA Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 55. IQVIA Recent Development Table 56. EXTEDO Company Information Table 57. EXTEDO Business Overview Table 58. EXTEDO Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. EXTEDO Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 60. EXTEDO Recent Development Table 61. RxLogix Company Information Table 62. RxLogix Business Overview Table 63. RxLogix Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. RxLogix Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 65. RxLogix Recent Development Table 66. Ennov Company Information Table 67. Ennov Business Overview Table 68. Ennov Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Ennov Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 70. Ennov Recent Development Table 71. Uppsala Monitoring Centre Company Information Table 72. Uppsala Monitoring Centre Business Overview Table 73. Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 75. Uppsala Monitoring Centre Recent Development Table 76. Medidata Company Information Table 77. Medidata Business Overview Table 78. Medidata Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Medidata Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 80. Medidata Recent Development Table 81. Clarivate Company Information Table 82. Clarivate Business Overview Table 83. Clarivate Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Clarivate Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 85. Clarivate Recent Development Table 86. AB Cube Company Information Table 87. AB Cube Business Overview Table 88. AB Cube Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. AB Cube Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 90. AB Cube Recent Development Table 91. Cloudbyz Company Information Table 92. Cloudbyz Business Overview Table 93. Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 95. Cloudbyz Recent Development Table 96. Cognizant Technology Company Information Table 97. Cognizant Technology Business Overview Table 98. Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 100. Cognizant Technology Recent Development Table 101. Taimei Technology Company Information Table 102. Taimei Technology Business Overview Table 103. Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 105. Taimei Technology Recent Development Table 106. eMedyun Company Information Table 107. eMedyun Business Overview Table 108. eMedyun Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. eMedyun Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 110. eMedyun Recent Development Table 111. Bioknow Company Information Table 112. Bioknow Business Overview Table 113. Bioknow Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Bioknow Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 115. Bioknow Recent Development Table 116. Singedi Health Company Information Table 117. Singedi Health Business Overview Table 118. Singedi Health Drug Safety and Pharmacovigilance (PV) Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Singedi Health Drug Safety and Pharmacovigilance (PV) Software Product Portfolio Table 120. Singedi Health Recent Development Table 121. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026) & (US$ Million) Table 122. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032) & (US$ Million) Table 123. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026) & (US$ Million) Table 124. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032) & (US$ Million) Table 125. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026) & (US$ Million) Table 127. North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (US$ Million) & (2027-2032) Table 128. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026) & (US$ Million) Table 129. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032) & (US$ Million) Table 130. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026) & (US$ Million) Table 134. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (US$ Million) & (2027-2032) Table 135. China Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026) & (US$ Million) Table 136. China Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032) & (US$ Million) Table 137. China Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026) & (US$ Million) Table 138. China Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032) & (US$ Million) Table 139. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026) & (US$ Million) Table 140. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032) & (US$ Million) Table 141. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026) & (US$ Million) Table 142. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032) & (US$ Million) Table 143. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Region (US$ Million) & (2021-2026) Table 145. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Region (US$ Million) & (2027-2032) Table 146. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026) & (US$ Million) Table 147. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032) & (US$ Million) Table 148. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026) & (US$ Million) Table 149. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032) & (US$ Million) Table 150. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026) & (US$ Million) Table 152. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (US$ Million) & (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Drug Safety and Pharmacovigilance (PV) Software Image Figure 2. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Share 2021 VS 2025 VS 2032 Figure 4. On-Premises Image Figure 5. Cloud-Based Image Figure 6. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drug Safety and Pharmacovigilance (PV) Software Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharma and Biotech Companies Image Figure 9. Contract Research Organizations (CROs) Image Figure 10. Business Process Outsourcing (BPO) Firms Image Figure 11. Other Image Figure 12. Global Drug Safety and Pharmacovigilance (PV) Software Market Size (US$ Million) & (2021-2032) Figure 13. Global Drug Safety and Pharmacovigilance (PV) Software Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drug Safety and Pharmacovigilance (PV) Software Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drug Safety and Pharmacovigilance (PV) Software Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Type (2021-2032) Figure 20. Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Application (2021-2032) Figure 23. North America Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032) Figure 25. North America Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032) Figure 26. North America Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Country (2021-2032) Figure 27. United States Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032) Figure 32. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032) Figure 33. Europe Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Country (2021-2032) Figure 34. Germany Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032) Figure 44. China Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032) Figure 45. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032) Figure 47. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032) Figure 48. Asia Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Region (2021-2032) Figure 49. Japan Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032) Figure 57. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032) Figure 58. SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Country (2021-2032) Figure 59. Brazil Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drug Safety and Pharmacovigilance (PV) Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • On-Premises
  • Cloud-Based
Applications
  • Pharma and Biotech Companies
  • Contract Research Organizations (CROs)
  • Business Process Outsourcing (BPO) Firms
  • Other
Companies covered
  • Oracle
  • Veeva Systems
  • ArisGlobal
  • IQVIA
  • EXTEDO
  • RxLogix
  • Ennov
  • Uppsala Monitoring Centre
  • Medidata
  • Clarivate
  • AB Cube
  • Cloudbyz
  • Cognizant Technology
  • Taimei Technology
  • eMedyun
  • Bioknow
  • Singedi Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug Safety and Pharmacovigilance (PV) Software Market by Type
  3. 1.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 On-Premises
  5. 1.2.3 Cloud-Based
  6. 1.3 Drug Safety and Pharmacovigilance (PV) Software Market by Application
  7. 1.3.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharma and Biotech Companies
  9. 1.3.3 Contract Research Organizations (CROs)
  10. 1.3.4 Business Process Outsourcing (BPO) Firms
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drug Safety and Pharmacovigilance (PV) Software Market Dynamics
  1. 2.1 Drug Safety and Pharmacovigilance (PV) Software Industry Trends
  2. 2.2 Drug Safety and Pharmacovigilance (PV) Software Industry Drivers
  3. 2.3 Drug Safety and Pharmacovigilance (PV) Software Industry Opportunities and Challenges
  4. 2.4 Drug Safety and Pharmacovigilance (PV) Software Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Perspective (2021-2032)
  2. 3.2 Global Drug Safety and Pharmacovigilance (PV) Software Growth Trends by Region
  3. 3.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Players
  2. 4.1.1 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug Safety and Pharmacovigilance (PV) Software Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug Safety and Pharmacovigilance (PV) Software Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug Safety and Pharmacovigilance (PV) Software Key Players Headquarters & Area Served
  7. 4.4 Global Drug Safety and Pharmacovigilance (PV) Software Players, Product Type & Application
  8. 4.5 Global Drug Safety and Pharmacovigilance (PV) Software Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug Safety and Pharmacovigilance (PV) Software Market CR5 and HHI
  11. 4.6.3 2025 Drug Safety and Pharmacovigilance (PV) Software Tier 1, Tier 2, and Tier 3
5 Drug Safety and Pharmacovigilance (PV) Software Market Size by Type
  1. 5.1 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2032)
  3. 5.3 Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Type (2021-2032)
6 Drug Safety and Pharmacovigilance (PV) Software Market Size by Application
  1. 6.1 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2032)
  3. 6.3 Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Oracle
  2. 7.1.1 Oracle Company Information
  3. 7.1.2 Oracle Business Overview
  4. 7.1.3 Oracle Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Oracle Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  6. 7.1.5 Oracle Recent Developments
  7. 7.2 Veeva Systems
  8. 7.2.1 Veeva Systems Company Information
  9. 7.2.2 Veeva Systems Business Overview
  10. 7.2.3 Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  12. 7.2.5 Veeva Systems Recent Developments
  13. 7.3 ArisGlobal
  14. 7.3.1 ArisGlobal Company Information
  15. 7.3.2 ArisGlobal Business Overview
  16. 7.3.3 ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  18. 7.3.5 ArisGlobal Recent Developments
  19. 7.4 IQVIA
  20. 7.4.1 IQVIA Company Information
  21. 7.4.2 IQVIA Business Overview
  22. 7.4.3 IQVIA Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  23. 7.4.4 IQVIA Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  24. 7.4.5 IQVIA Recent Developments
  25. 7.5 EXTEDO
  26. 7.5.1 EXTEDO Company Information
  27. 7.5.2 EXTEDO Business Overview
  28. 7.5.3 EXTEDO Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  29. 7.5.4 EXTEDO Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  30. 7.5.5 EXTEDO Recent Developments
  31. 7.6 RxLogix
  32. 7.6.1 RxLogix Company Information
  33. 7.6.2 RxLogix Business Overview
  34. 7.6.3 RxLogix Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  35. 7.6.4 RxLogix Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  36. 7.6.5 RxLogix Recent Developments
  37. 7.7 Ennov
  38. 7.7.1 Ennov Company Information
  39. 7.7.2 Ennov Business Overview
  40. 7.7.3 Ennov Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Ennov Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  42. 7.7.5 Ennov Recent Developments
  43. 7.8 Uppsala Monitoring Centre
  44. 7.8.1 Uppsala Monitoring Centre Company Information
  45. 7.8.2 Uppsala Monitoring Centre Business Overview
  46. 7.8.3 Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  48. 7.8.5 Uppsala Monitoring Centre Recent Developments
  49. 7.9 Medidata
  50. 7.9.1 Medidata Company Information
  51. 7.9.2 Medidata Business Overview
  52. 7.9.3 Medidata Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Medidata Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  54. 7.9.5 Medidata Recent Developments
  55. 7.10 Clarivate
  56. 7.10.1 Clarivate Company Information
  57. 7.10.2 Clarivate Business Overview
  58. 7.10.3 Clarivate Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Clarivate Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  60. 7.10.5 Clarivate Recent Developments
  61. 7.11 AB Cube
  62. 7.11.1 AB Cube Company Information
  63. 7.11.2 AB Cube Business Overview
  64. 7.11.3 AB Cube Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AB Cube Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  66. 7.11.5 AB Cube Recent Developments
  67. 7.12 Cloudbyz
  68. 7.12.1 Cloudbyz Company Information
  69. 7.12.2 Cloudbyz Business Overview
  70. 7.12.3 Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  72. 7.12.5 Cloudbyz Recent Developments
  73. 7.13 Cognizant Technology
  74. 7.13.1 Cognizant Technology Company Information
  75. 7.13.2 Cognizant Technology Business Overview
  76. 7.13.3 Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  78. 7.13.5 Cognizant Technology Recent Developments
  79. 7.14 Taimei Technology
  80. 7.14.1 Taimei Technology Company Information
  81. 7.14.2 Taimei Technology Business Overview
  82. 7.14.3 Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  84. 7.14.5 Taimei Technology Recent Developments
  85. 7.15 eMedyun
  86. 7.15.1 eMedyun Company Information
  87. 7.15.2 eMedyun Business Overview
  88. 7.15.3 eMedyun Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  89. 7.15.4 eMedyun Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  90. 7.15.5 eMedyun Recent Developments
  91. 7.16 Bioknow
  92. 7.16.1 Bioknow Company Information
  93. 7.16.2 Bioknow Business Overview
  94. 7.16.3 Bioknow Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bioknow Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  96. 7.16.5 Bioknow Recent Developments
  97. 7.17 Singedi Health
  98. 7.17.1 Singedi Health Company Information
  99. 7.17.2 Singedi Health Business Overview
  100. 7.17.3 Singedi Health Drug Safety and Pharmacovigilance (PV) Software Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Singedi Health Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
  102. 7.17.5 Singedi Health Recent Developments
8 North America
  1. 8.1 North America Drug Safety and Pharmacovigilance (PV) Software Revenue (2021-2032)
  2. 8.2 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032)
  5. 8.3 North America Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032)
  9. 8.5 North America Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country
  11. 8.6.1 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue (2021-2032)
  2. 9.2 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032)
  5. 9.3 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032)
  9. 9.5 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country
  11. 9.6.1 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug Safety and Pharmacovigilance (PV) Software Revenue (2021-2032)
  2. 10.2 China Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2032)
  3. 10.2.1 China Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026)
  4. 10.2.2 China Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032)
  5. 10.3 China Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032)
  6. 10.4 China Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2032)
  7. 10.4.1 China Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026)
  8. 10.4.2 China Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032)
  9. 10.5 China Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue (2021-2032)
  2. 11.2 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032)
  5. 11.3 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032)
  9. 11.5 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Country
  11. 11.6.1 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue (2021-2032)
  2. 12.2 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country
  11. 12.6.1 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug Safety and Pharmacovigilance (PV) Software Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst